linjc16/ctgov huggingface dataset:
Ultrasound to Verify Lung-isolation During Single-lung Ventilation

Study Overview
=================
Brief Summary
-----------------
The purpose of the current study is to prospectively evaluate the usefulness of thoracic ultrasonography in demonstrating effective lung isolation during single-lung ventilation (SLV) in the pediatric patient. The primary hypothesis is that ultrasonography will accurately verify lung separation during SLV, as compared to fiberoptic bronchoscope (FOB).

Official Title
-----------------
Ultrasound to Verify Lung-isolation During Single-lung Ventilation

Conditions
-----------------
Thoracic Diseases

Intervention / Treatment
-----------------
* Device: Portable, Point-of-Care Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Requiring single lung ventilation for thoracic surgery Exclusion Criteria: None

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ultrasonography<br>Patients requiring single lung ventilation for a surgical procedure will have a bedside ultrasound to evaluate lung isolation. | Device: Portable, Point-of-Care Ultrasound<br>* Portable ultrasonography done at the bedside.<br>* Other names: SonoSite;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The accuracy of using ultrasound to assess lung isolation by visualizing lung movement or lack thereof of both the operative and non-operative lung fields. | Ultrasound will be used to look for lung sliding in the ventilated lung field and lack of lung sliding and presence of lung pulse on the operative/isolated lung field. The effectiveness of this modality will also be compared to the use of fiberoptic bronchoscopy and lung auscultation for assessing lung isolation, which are the current accepted standards of care. | Within 5 minutes of intubation and single lung ventilation device placement | 
| Time to confirm lung isolation | Compare the time required to confirm lung isolation using auscultation, FOB, and ultrasound. | Within 5 minutes of intubation and single lung ventilation device placement |
Chronic Pain Attitudes Medical and Physiotherapy Students

Study Overview
=================
Brief Summary
-----------------
This is an analysis of data collected from 2009-2014 from medical students at GCU and physiotherapy students at UoG measuring attitudes towards patients with chronic low back pain and their functionality.

Detailed Description
-----------------
This is longitudinal study with the data collected from 2009-2014 from medical students and physiotherapy students at two different Scottish universities measuring attitudes towards patients with chronic low back pain and their functionality. The outcome measure used was HC-PAIRS the original 15 point Likert Scale. Data was analysed using SPSS (version 25). All data was found to be normally distributed. Descriptive statistics were presented as mean (Standard Deviation). Inferential statistics were carried out using a two-way ANOVA with year of study and discipline of degree as independent variables with post hoc analysis. A p-value of <0.05 was considered statistically significant.

Official Title
-----------------
Understanding Attitudes and Beliefs of Undergraduate Medical and Physiotherapy Students - a Longitudinal Study

Conditions
-----------------
Chronic Low Back Pain

Intervention / Treatment
-----------------
* Other: Physiotherapy students
* Other: Medical students


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Engaged in the 2009 physiotherapy degree at Two Scottish universities Exclusion Criteria: -Anyone who is not on the above degree courses.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Physiotherapy students<br>Degree course | Other: Physiotherapy students<br> <br> |
| Medical students<br>Degree course | Other: Medical students<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HC-PAIRS (Health care providers pain and impairment relationship scale) | 15 point Likert Scale ranging in score from 15 to105 with a low score reflecting an attitude towards patients with pain and their functionality which is in keeping with best evidence research and scientific knowledge. Subscales are not valid for this outcome measure. | 1 x year for duration of degree course at start of first semester | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
attitudes, chronic low back pain, functionality, healthcare professional students
Thrombogenic Factors and Recurrent Coronary Events

Study Overview
=================
Brief Summary
-----------------
To determine if selected circulating blood factors that reflect enhanced thrombogenesis are associated with an increased incidence of recurrent coronary events, including cardiac death or non-fatal myocardial infarction.

Detailed Description
-----------------
DESIGN NARRATIVE: In this multicenter, collaborative, prospective study, patients hospitalized with a myocardial infarction were enrolled from ten geographically dispersed centers. Five thrombogenic- related blood factors were quantitated, and formed the centerpiece of this study: 1) lipoprotein(a) [Lp(a)] - a quantitative genetic factor that contains apolipoprotein B, has a structural homology to plasminogen, interferes with intrinsic thrombolytic activity, and represents a crossover link in the thrombogenesis/atherogenesis hypothesis; 2) soluble fibrin - a system indicator of coagulation activity in the ongoing conversion of fibrinogen to insoluble fibrin strands; 3) plasminogen activator inhibitor-1 (PAI-1) - an important regulator of the fibrinolytic system, it interferes with intrinsic t-PA activity; 4) coagulation Factor VII -high levels lead to increased thrombogenesis and have been associated with an increased risk of ischemic heart disease; and- 5) von Willebrand factor - it binds to platelet glycoproteins, contributes to local thrombus formation, and it is elevated in patients at increased risk of coronary thrombosis. The primary analysis utilized a time-dependent survivors hip model (Cox regression) to determine the presence or absence of an association between one or more of these factors and subsequent thrombotic-related coronary events. Secondary objectives included: 1) to determine if there was a statistical association between the thrombogenic factors and conventional hematologic/lipid parameters, and to evaluate their interactions regarding coronary events; and 2) to determine if thrombogenic factors had uniform effects on coronary event rates across various subgroups.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Coronary Disease, Myocardial Infarction, Thrombosis, Death, Sudden, Cardiac

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Implementation of the HELIOSTARTM in Real-world Clinical Practice at a High-volume Center

Study Overview
=================
Brief Summary
-----------------
The HELIOSTARTM catheter (Biosense Webster) is a new technology for pulmonary vein isolation (PVI) in atrial fibrillation (AF), combining radiofrequency (RF)-ablation and 3D-mapping visualization with the concept of single-shot-ablation device. This study evaluates the operator learning curve und procedural outcome during implementation of the HELIOSTARTM.

Detailed Description
-----------------
The first patients undergoing PVI by HELIOSTARTM at Heidelberg University Hospital are included in this prospective study. Procedures are performed by an operator proficient in CB-ablation. Procedural outcome was analyzed over the course of increasing experience with the device and in comparison to a previous cohort investigated during implementation of the Arctic FrontTM-cryoballoon (Medtronic).

Official Title
-----------------
Implementation of the HELIOSTARTM in Real-world Clinical Practice at a High-volume Center - Operator Learning Curve and Procedural Outcome Parameters

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Device: Pulmonary vein isolation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥18 years, ability to provide informed consent and at least one episode of documented paroxysmal or persistent AF Exclusion Criteria: history of prior AF ablation, left atrial thrombus, suspected irregular PV-anatomy in pre-procedural transesophageal echocardiography (TOE) or contraindication for peri-procedural anticoagulation therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Pulmonary vein isolation|Local electrical isolation of PV ostia to prevent recurrence of AF due to ectopic PV-triggers|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Procedure duration |  | Day of index procedure, number of minutes | 
| LA dwell time | Minutes | Day of index procedure, number of minutes | 
| Fluoroscopy duration | Minutes | Day of index procedure, number of minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Short-term AF arrhythmia recurrence | ECG-documented AF | 3 months | 
| Procedural complications | As diagnosed by physician and documented in written report | 3 months | 
| Long-term arrhythmia recurrence | ECG-documented AF | 12 months |
Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients

Study Overview
=================
Brief Summary
-----------------
What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China.

Detailed Description
-----------------
There is no evidence of treatment after progression of Ful. We retrospectively evaluated HR+, HER2- MBC patients failed on Ful 500mg as first line or second line therapy from 2014 to 2017 in 6 institutions. Treatment pattern, PFS, OS and safety were analyzed to figure out the situation and efficacy of treatment after Fulvestrant.

Official Title
-----------------
What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who were treated with Fulvestrant between June 2014 to June 2017 as first line or second line therapy Patients received subsequent treatment after progressing on Fulvestrant for at least one cycle (>1 month) Complete medical history was available Exclusion Criteria: Subsequent treatment was not standard therapy (cannot be classified into endocrine therapy/ chemotherapy) Medical history was incomplete
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Endocrine therapy<br>use endocrine therapy (ET) after Fulvestrant, include but not limited to: tamoxifen, anastrozole, letrozole, exemestane, exemestane + everolimus | |
| Chemotherapy<br>use Chemotherapy (CT) after Fulvestrant, include but not limited to: capecitabine, docetaxel-based, vinorelbine, paclitaxel-based | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | Progression free survival | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | Overall survival | From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | 
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fulvestrant, Progression, Endocrine sensitivity
Identification of Biomarkers for Patients With Vascular Anomalies

Study Overview
=================
Brief Summary
-----------------
The study will use blood (serum and plasma) and tissue obtained from participants undergoing prescribed surgical resection of vascular anomalies of interest proposed in this study. The study will also use blood (serum and plasma) and tissue collected and stored in a tissue bank maintained by the Department of Hematology/Oncology.

Detailed Description
-----------------
While vascular anomalies are rare diseases, they can be life-threatening and devastating to affected children and their families. Advances in diagnosis, monitoring and therapies will be significantly improved if non-invasive biomarkers that are sensitive and specific can be identified. Obtaining a tissue biopsy to help in diagnosis can actually worsen the disease and so identification of specific blood biomarkers is highly desirable. Studies will measure angiogenic factors in serum and plasma samples at baseline and on therapy. Tissue removed during surgical resection or blood removed prior to sclerotherapy will be used to obtain cells and tissue for the assessment of where biomarkers are coming from and to identify disease-causing pathways for new therapeutic targeting.

Official Title
-----------------
Identification of Biomarkers for Patients With Vascular Anomalies

Conditions
-----------------
Vascular Anomaly, Generalized Lymphatic Anomaly, Kaposiform Hemangioendothelioma, Kaposiform Lymphangiomatosis, Gorham-Stout Disease, Klippel Trenaunay Syndrome, Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient having labs drawn as standard of care will have blood drawn for the study if consented/ assented. All patients who are undergoing a surgical procedure or sclerotherapy are currently consented for participation in the tissue bank. Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 1 Day

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of Biomarkers with Differential Diagnosis |  | An Average of Every 2 Years | 
| Correlation of Biomarkers with Disease Severity |  | An Average of Every 2 Years | 
| Correlation of Biomarkers with Response to Therapies |  | An Average of Every 2 Years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Generalized Lymphatic Anomaly, Vascular Anomaly, Kaposiform Hemangioendothelioma, Kaposiform Lymphangiomatosis, Vascular Endothelial Growth Factor, Biomarkers, GLA, KLA, KHE, GSD
Comparison of Two Surgical Techniques to Treat Knock Knees in Children

Study Overview
=================
Brief Summary
-----------------
Knock knees or genu valgus necessitates in some children corrective surgery with partial closure of the growth plate at level of the knee.

Detailed Description
-----------------
Background: Genu valgus is a condition with malalignment of the lower extremity. Surgery may be indicated in severe cases and reversible hemiepiphysiodesis is often the treatment of choice in growing children. Partial closure can be obtained by stapling technique or with a new treatment called tension band plating.

Official Title
-----------------
Reversible Hemiepiphysiodesis in Children - Stapling Versus Eight Plate

Conditions
-----------------
Genu Valgus

Intervention / Treatment
-----------------
* Procedure: Hemiepiphysiodesis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: genu valgus remaining growth Exclusion Criteria: systemic disease unilateral disease

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Hemiepiphysiodesis|Partial closure of growth plate to correct deformity|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment time |  | up to 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain score post operatively |  | up to 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hemiepiphysiodesis
SWAN: Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01)

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the efficacy of a new thickened formula on regurgitation

Official Title
-----------------
Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01)

Conditions
-----------------
Gastroesophageal Reflux

Intervention / Treatment
-----------------
* Dietary Supplement: Thickened infant formula


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants : Aged ≤ 5 months old fully formula fed with at least 5 episodes of regurgitation per day, for at least a week Exclusion Criteria: Breast fed infants Infants presenting symptoms of a complicated gastroesophageal reflux Infants presenting intestinal disorders

Ages Eligible for Study
-----------------
Minimum Age: 1 Week
Maximum Age: 5 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Thickened infant formula<br> | Dietary Supplement: Thickened infant formula<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of episodes of regurgitation per day |  | 14 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Regurgitation score assessed through Vandenplas score |  | 14 and 90 days | 
| Stools frequency over 72h |  | 14 and 90 days | 
| Stools consistency assessed through Bristol Stool form Scale |  | 14 and 90 days | 
| Weight expressed in z scores according to the WHO Child Growth Standards |  | 90 days | 
| Height expressed in z scores according to the WHO Child Growth Standards |  | 90 days | 
| BMI expressed in z scores according to the WHO Child Growth Standards |  | 90 days | 
| Head circumference expressed in z scores according to the WHO Child Growth Standards |  | 90 days |
Relationship Between Dosage of Clopidogrel and Platelet Aggregation in Chinese With Different Genotype

Study Overview
=================
Brief Summary
-----------------
This study is a prospective, observational study to estimate the relationship between dosage of clopidogrel and platelet aggregation in Chinese with different genotype. The investigators suppose both pretreatment dosage of clopidogrel before percutaneous coronary intervention (PCI) and CYP2C19 genotype may effect the platelet aggregation as well as clinical outcome.

Conditions
-----------------
Coronary Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: accept PCI in Chinese CHD patients expected dual antiplatelet therapy (DAPT) at least 6 months Exclusion Criteria: another planned PCI within 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Low dose - Wild genotype (LW)<br>75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 wild genotype | |
| Low dose - Variant genotype (LV)<br>75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 variant genotype | |
| High dose - Wild genotype (HW)<br>300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 wild genotype | |
| High dose - Variant genotype (HV)<br>300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 variant genotype | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in platelet aggregation |  | 1 month and 6 months after PCI | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiovascular events (MACE); Bleeding events |  | 6 months after PCI |